Sleep Architecture and Longevity: Glymphatic System, Sleep Apnea, and Diabetic Neuropathy

Sleep Architecture and Longevity: Glymphatics, Sleep Stages, Apnea, and the DPN Sleep Cycle

Sleep was, for much of 20th century medicine, considered a passive state — a necessary inconvenience during which the body was simply offline. The past two decades of sleep neuroscience have overturned this view completely. Sleep is now understood as an intensely active biological process during which the brain performs critical maintenance, the immune system consolidates memory and clears cellular damage, metabolic systems reset, and hormonal cascades essential for tissue repair and growth hormone release unfold.

The longevity consequences of chronic sleep deprivation — now affecting an estimated 35% of American adults who regularly sleep less than 7 hours — are not subtle. They operate across virtually every biological aging pathway: accelerating epigenetic clock advancement, increasing inflammaging, impairing mitochondrial function, promoting insulin resistance, elevating cortisol and sympathetic nervous system tone, and — most strikingly — allowing amyloid-beta and tau to accumulate in the brain by impairing the glymphatic clearance system that depends on slow-wave sleep.

Table of Contents

• Sleep Architecture: The Four Stages and Their Distinct Functions
• The Glymphatic System: Sleep’s Brain Housekeeping Role
• Sleep Duration and Mortality: The U-Shaped Curve
• Slow-Wave Sleep and Metabolic Longevity
• Sleep Apnea: The Silent Longevity Destroyer
• Circadian-Sleep Interaction: Why Timing Matters as Much as Duration
• Diabetes, DPN, and Sleep: The Destructive Cycle
• The Sleep Longevity Protocol
• Frequently Asked Questions
• The Bottom Line
• Sources

Sleep Architecture: The Four Stages and Their Distinct Biological Functions

Adult sleep cycles through four distinct stages in 90-minute cycles, with 4–6 complete cycles per night forming the normal sleep architecture. Each stage serves specific and non-substitutable biological functions — skipping or compressing any stage has consequences that cannot be compensated by extending other stages.

N1 (Light NREM sleep): The transition stage from wakefulness, typically lasting 1–7 minutes per cycle. N1 is characterized by the appearance of theta waves (4–8 Hz) on EEG, slowing heart rate, relaxing muscles, and the cessation of eye movement. Its primary role appears to be the initiation of the sleep state rather than specific restorative functions. N1 sleep is the most easily disrupted by noise or movement, making sleep continuity important for preventing excessive N1.

N2 (Intermediate NREM sleep): The most abundant sleep stage by duration, comprising approximately 45–55% of total sleep time in adults. N2 is characterized by sleep spindles (12–15 Hz oscillations) and K-complexes on EEG — both of which appear to play active roles in memory consolidation by coordinating hippocampal-neocortical information transfer. Sleep spindle density is directly associated with procedural learning and is reduced in older adults, contributing to age-related memory consolidation deficits. N2 is also when the body temperature drop deepens, further reducing metabolic rate to facilitate cellular repair.

N3 (Slow-Wave Sleep / Deep Sleep): The most restorative stage by virtually every metabolic and cellular measure. N3 is characterized by high-amplitude delta waves (0.5–4 Hz) on EEG, near-complete muscle paralysis, the lowest heart rate and blood pressure of the sleep period, and the highest output of growth hormone (80–90% of the day’s GH is released during N3, under direct GHRH stimulation by the suprachiasmatic nucleus). N3 is when glymphatic waste clearance peaks, immune memory consolidation occurs, tissue repair peptides are released, and the autonomic nervous system undergoes its deepest recovery. N3 declines dramatically with age — adolescents spend 20–25% of sleep time in N3; adults over 65 often spend less than 5% — and this decline is one of the most important mechanisms through which aging impairs sleep’s longevity function.

REM (Rapid Eye Movement sleep): REM sleep, comprising 20–25% of total sleep time in young adults, is the stage of intense neurological activity, vivid dreaming, and emotional memory processing. The brain during REM shows activity patterns nearly identical to wakefulness, but the body is in a state of motor paralysis (mediated by glycinergic and GABAergic inhibition of motor neurons). REM sleep is essential for emotional regulation (deficits in REM are strongly associated with anxiety, PTSD, and depression), creative problem-solving (offline memory recombination), and the pruning of unnecessary synaptic connections formed during the day. REM proportion increases toward morning in the final cycles of the night — meaning early morning alarm interruption disproportionately truncates REM sleep.

The Glymphatic System: Sleep’s Brain Housekeeping Mechanism

The discovery of the glymphatic system by Maiken Nedergaard’s laboratory at the University of Rochester (Science, 2013) represents one of the most significant neuroscience advances of the past decade in terms of longevity implications. The glymphatic system is a brain-wide waste clearance network that uses cerebrospinal fluid (CSF) flowing through perivascular channels surrounding cerebral arteries and veins to flush metabolic waste products from brain interstitial tissue — analogous to the lymphatic system’s role in peripheral tissues (which the brain largely lacks).

The critical longevity finding: glymphatic flow increases by approximately 60% during NREM slow-wave sleep compared to wakefulness, driven by neuronal synchronization that produces interstitial space expansion (allowing CSF to penetrate more efficiently into brain tissue). During wakefulness, the metabolic demands of neural activity generate substantial waste products — including amyloid-beta (Aβ) peptides and tau protein — that accumulate in the interstitium faster than glymphatic clearance can remove them. Sleep reverses this accumulation by dramatically upregulating CSF-driven waste flushing.

Xie et al. (2013) demonstrated that just one night of sleep deprivation significantly elevated amyloid-beta levels in the mouse brain — and subsequent human PET imaging studies confirmed that even partial sleep restriction (6 hours/night) increased Aβ accumulation measurably within days in healthy human subjects. The long-term implication: chronic short sleep — experienced by 35% of American adults — may represent one of the largest modifiable risk factors for Alzheimer’s disease, operating through the glymphatic Aβ clearance mechanism rather than through any genetic pathway.

The glymphatic system is maximally active during N3 slow-wave sleep and is also preferentially activated in the lateral (side-lying) sleeping position versus supine, due to differences in CSF dynamics. The clinical implication: N3 slow-wave sleep quality and duration, not just total sleep time, is the key determinant of glymphatic clearance efficacy — and interventions that increase N3 (exercise, temperature optimization, alcohol avoidance) may have direct Alzheimer’s prevention significance.

Sleep Duration and Mortality: The U-Shaped Curve Explained

The relationship between sleep duration and mortality follows a robust U-shaped curve in large population studies — with both short sleep (under 6 hours) and long sleep (over 9 hours) associated with elevated mortality compared to the 7–8 hour optimum. This has been replicated across dozens of cohort studies in multiple countries and demographic groups.

The short sleep mortality association is the most mechanistically understood arm of the U-curve. Multiple mechanisms contribute: elevated evening cortisol from chronic sleep restriction drives visceral fat accumulation, insulin resistance, and suppression of growth hormone and testosterone. Sleep deprivation activates NF-κB and upregulates pro-inflammatory cytokines (IL-6, TNF-α, CRP) through a well-characterized pathway involving adenosine accumulation and hypothalamic-pituitary-adrenal axis dysregulation. Short sleep reduces NK cell activity by 70% per night of significant restriction (Irwin et al., 2010) — a magnitude of immune suppression with direct cancer surveillance implications. Cardiovascular risk increases: a 2019 meta-analysis (Liu et al., European Heart Journal) found that sleeping less than 6 hours was associated with a 20% higher risk of heart attack and 15% higher stroke risk.

The long sleep mortality association (>9 hours) is more complex. Unlike short sleep — which appears to directly cause harm — long sleep duration is largely a marker of underlying illness (depression, heart failure, chronic disease, sleep apnea causing fragmented but long total sleep time) rather than a cause of mortality. Healthy older adults who naturally sleep 8–9 hours do not show elevated mortality in studies that control for health status. The practical guidance: long sleep in a previously normal-sleep individual warrants clinical investigation for underlying causes rather than behavioral restriction.

Sleep Apnea: The Silent Longevity Destroyer

Obstructive sleep apnea (OSA) — the cyclical collapse of the upper airway during sleep producing repeated apnea events (cessation of breathing), arousals, and oxygen desaturation — affects an estimated 30 million Americans, with approximately 80% undiagnosed. It is the single most important and actionable sleep disorder for longevity medicine, because its consequences are severe, its detection is straightforward, and its treatment is highly effective.

The longevity consequences of untreated OSA operate through multiple parallel mechanisms. Repeated nocturnal hypoxemia — even brief desaturations to 85–90% O2 saturation occurring dozens to hundreds of times per night — activates hypoxia-inducible factor 1α (HIF-1α), upregulates sympathetic nervous system outflow, elevates inflammatory cytokines, and promotes oxidative stress in vascular endothelium. The Wisconsin Sleep Cohort Study (Young et al.) found that OSA with an apnea-hypopnea index (AHI) greater than 30 events/hour was associated with a 3-fold increase in all-cause mortality over 18 years of follow-up, with cardiovascular mortality showing even stronger associations. OSA doubles the risk of hypertension, increases risk of atrial fibrillation 2-4 fold, and is independently associated with metabolic syndrome and T2DM.

The OSA-cognitive decline-Alzheimer’s connection is mechanistically compelling. Nocturnal hypoxemia directly impairs glymphatic function by reducing the slow-wave sleep during which glymphatic clearance peaks. A 2017 study in JAMA Neurology (Lim et al.) found that OSA severity independently predicted higher amyloid-beta burden on PET imaging after controlling for age, BMI, and other Alzheimer’s risk factors. Effective CPAP treatment reduces these biomarkers and improves cognitive measures over 12 months in multiple RCTs — among the strongest evidence that a treatable condition directly affects Alzheimer’s risk through an identified biological mechanism.

OSA is substantially more prevalent in patients with T2DM and DPN than in the general population. The Wisconsin Sleep Cohort data and multiple diabetes-specific studies find OSA prevalence of 50–80% in obese T2DM patients and 30–50% even in non-obese T2DM patients. The bidirectional relationship: T2DM worsens OSA (autonomic neuropathy impairs upper airway muscle responsiveness; visceral fat increases neck circumference and pharyngeal crowding), while OSA worsens T2DM (intermittent hypoxemia impairs pancreatic beta cell function, increases insulin resistance through HIF-1α and sympathetic activation). Treating OSA in T2DM patients improves insulin sensitivity, reduces nocturnal blood pressure surges, and reduces the inflammatory milieu driving DPN progression.

Clinical identification: the Epworth Sleepiness Scale (ESS >10), STOP-BANG questionnaire (score ≥3), and morning headache with unrefractive fatigue are the primary screening tools. Home sleep apnea testing (HSAT) devices have made diagnosis accessible without polysomnography in most uncomplicated cases. CPAP (continuous positive airway pressure) remains the most effective OSA treatment, with adherence being the primary limitation. For patients intolerant of CPAP, mandibular advancement devices (MADs) and — in select anatomical candidates — hypoglossal nerve stimulation (Inspire device) provide alternatives with strong evidence bases.

Circadian-Sleep Interaction: Why Sleep Timing Matters

Sleep timing is regulated by the interaction of two systems: the circadian clock (reviewed in our circadian longevity post) and sleep homeostasis (adenosine accumulation during wakefulness driving sleep pressure). Sleep quality is maximized when sleep timing aligns with the individual’s circadian phase — the window of natural circadian sleep propensity. Misalignment between sleep timing and circadian phase (as in shift workers or severe evening chronotypes forced into early schedules) produces sleep that is architecturally abnormal even when duration is adequate: reduced N3 slow-wave sleep, reduced REM density, and impaired consolidation.

For longevity purposes, two circadian-sleep interactions are particularly important. First, core body temperature nadir occurs approximately 2 hours before natural wake time and coincides with peak N3 sleep pressure and growth hormone release — the biological reason why sleeping in a cool room (65–68°F / 18–20°C) substantially improves N3 depth by accelerating the core temperature drop at sleep onset. Second, cortisol awakening response (CAR) peaks 30–45 minutes after waking and is driven by the circadian clock, not alarm timing — waking before your natural circadian phase truncates the final REM cycles and produces a blunted or absent CAR, impairing cognitive readiness for hours after waking.

Light exposure is the dominant circadian zeitgeber and the most powerful tool for sleep timing optimization. Morning light exposure (10–30 minutes of outdoor or 10,000 lux bright light therapy within 30 minutes of waking) anchors the circadian clock earlier and strengthens the sleep-wake amplitude. Evening blue light suppression (from screens, LED lighting) after 8 PM prevents the melatonin delay that keeps many people awake past their ideal sleep window. The practical protocol: morning light + evening darkness creates the light-dark contrast that the circadian clock requires to maintain normal amplitude and timing.

Diabetes, Diabetic Peripheral Neuropathy, and Sleep: The Destructive Feedback Cycle

Patients with T2DM and DPN face a particularly vicious sleep-disease interaction that accelerates both conditions simultaneously. Understanding the cycle — and its breakpoints — is essential for comprehensive DPN management.

DPN pain disrupts sleep architecture: Neuropathic pain — burning, tingling, lancinating sensations predominantly in the feet and legs — is characteristically worse at night when distracting sensory inputs are absent and thermal regulation changes alter nerve fiber sensitization. DPN pain increases awakenings, reduces N3 slow-wave sleep proportion, and fragments REM cycles. Studies find that 50–60% of DPN patients report sleep disturbances significantly affecting quality of life, with pain being the primary driver.

Sleep deprivation worsens insulin resistance: Even one night of partial sleep restriction (4 hours) reduces insulin sensitivity by 25% in healthy subjects (Spiegel et al., Lancet, 1999). The mechanism: elevated evening cortisol from sleep restriction reduces GLUT4 expression and insulin receptor downstream signaling; elevated sympathetic tone increases free fatty acid release, impairing insulin signaling in muscle. In T2DM patients with already-impaired insulin sensitivity, the additional sleep-deprivation-driven impairment drives HbA1c elevation and worsens postprandial glucose management.

Hyperglycemia worsens sleep: Nocturnal hyperglycemia promotes polyuria (nocturia), waking patients 2–4 times per night to urinate — independently disrupting sleep architecture. Hypoglycemic episodes (in insulin-treated patients) trigger sympathetic activation that fragments sleep. The glycemic volatility common in T2DM produces sleep fragmentation that directly impairs N3 and REM even in the absence of pain.

Sleep deprivation promotes DPN progression: Through elevated inflammatory cytokines (TNF-α, IL-6), oxidative stress, insulin resistance increase, and reduced growth hormone secretion (which supports peripheral nerve regeneration), chronic sleep deprivation accelerates the metabolic and neuroinflammatory pathways driving DPN. There is also emerging evidence that the peripheral nervous system has its own glymphatic-like clearance function during sleep — sleep deprivation may impair nerve tissue clearance of aggregated proteins analogously to the brain’s glymphatic dysfunction.

Restless legs syndrome (RLS) and DPN: RLS — the urge to move legs, often with uncomfortable sensations, worsening at rest and evening — is significantly more prevalent in DPN patients than controls (approximately 25% vs 5% in age-matched non-DPN populations). The mechanistic overlap between small fiber DPN and RLS is not fully established, but both involve peripheral sensory fiber dysfunction and both respond to dopaminergic and opioid pathways. For DPN patients with concurrent RLS, iron status assessment (ferritin target >75 mcg/L for RLS management) and sleep specialist referral are appropriate clinical steps.

The Sleep Longevity Protocol: Evidence-Based Optimization

Sleep Environment Optimization

Temperature: Bedroom temperature of 65–68°F (18–20°C) optimizes the core temperature drop at sleep onset that triggers N3 slow-wave sleep. Mattress cooling devices (ChiliPad, OOLER) show RCT evidence for improving N3 proportion. Warm bath or shower 1–2 hours before bed paradoxically improves sleep by promoting peripheral vasodilation that accelerates core temperature drop.

Light: Complete darkness during sleep prevents light-driven circadian phase disruption via retinal photoreceptors. Blackout curtains or sleep masks are evidence-supported. Blue light-blocking glasses (≥90% blue light filtration) worn from 2 hours before bed reduce melatonin delay in multiple RCTs (Ostrin et al., 2017).

Sound: Continuous low-level pink or white noise at 50–65 dB can reduce sleep-disrupting sound spikes by masking transient noises that would otherwise trigger micro-arousals. Sound consistency is more important than silence — irregular loud noises in an otherwise quiet environment are the most disruptive pattern.

Behavioral and Pharmacological Sleep Optimization

Alcohol: Alcohol is the most commonly used self-medication for sleep and has the most counterproductive effect on sleep architecture. Alcohol does accelerate sleep onset (via GABA-A receptor activation) but dramatically suppresses REM sleep in the first half of the night and increases N1 light sleep and awakenings in the second half. A 2020 meta-analysis (Colrain et al.) found dose-dependent suppression of both N3 and REM with even moderate alcohol consumption (1–2 drinks). Abstinence for 3+ hours before bed is the minimum; alcohol cessation produces measurable sleep quality improvement within 1–2 weeks.

Caffeine: Caffeine’s half-life of 5–7 hours means a 3 PM coffee still has 50% of its adenosine-blocking effect at 10 PM, substantially impairing sleep pressure at bedtime. The clinical target: no caffeine after noon for most people; after 10 AM for slow caffeine metabolizers (CYP1A2 slow variant). Morning caffeine timing after cortisol awakening response peak (30–90 min after waking) maximizes alertness benefit without disrupting cortisol signaling.

Low-dose melatonin: Melatonin at 0.5–1mg taken 1–2 hours before desired sleep onset is the appropriate longevity-supportive dose — far lower than the 5–10mg marketed supplements. High doses do not produce proportionally greater benefit and may reduce the pituitary’s natural melatonin sensitivity through receptor downregulation. Melatonin is most effective for circadian phase shifting (jet lag, shift work, delayed sleep phase) and less effective as a sedative for chronic insomnia. Long-term safety data for doses under 1mg are favorable.

Cognitive Behavioral Therapy for Insomnia (CBT-I): CBT-I is the first-line treatment for chronic insomnia (≥3 nights/week sleep difficulty for ≥3 months) per AASM guidelines, superior to pharmacotherapy for long-term outcomes. It includes sleep restriction therapy, stimulus control, sleep hygiene education, and cognitive restructuring of sleep-related anxiety. Digital CBT-I programs (Sleepio, Somryst) have completed RCTs showing efficacy comparable to in-person therapy, making this accessible without specialist referral.

Sleep Architecture and Longevity: Frequently Asked Questions

How much slow-wave sleep do you need for Alzheimer’s prevention?

There is no established minimum N3 dose for Alzheimer’s prevention — this is an active research area. What is established: N3 slow-wave sleep is when glymphatic amyloid-beta clearance peaks, and chronically reduced N3 (common in adults over 60, who often have less than 10% N3 versus 20% in young adults) is associated with elevated Aβ burden and accelerated cognitive decline in longitudinal studies. Interventions that increase N3 — exercise (most strongly supported: 150+ min/week of aerobic exercise increases N3 by 15–20% in RCTs), temperature optimization, alcohol avoidance, and possibly acoustic slow oscillation stimulation (a research-stage technique) — all improve Alzheimer’s-relevant biomarkers. The practical target: maximize N3 by optimizing sleep environment, exercise, timing, and alcohol avoidance rather than targeting a specific stage percentage.

Can you “catch up” on lost sleep on weekends?

Weekend recovery sleep partially compensates for some performance deficits from weekday sleep restriction but does not restore all biological consequences. A 2019 Current Biology study (Depner et al.) found that weekend recovery sleep did not fully reverse the metabolic effects of weekday sleep restriction — insulin sensitivity remained impaired, and social jet lag (the circadian phase disruption from shifting sleep timing by 2+ hours between weekdays and weekends) produced independent metabolic harm. The immunological and glymphatic consequences of weekday sleep restriction appear similarly incompletely reversed by weekend recovery. The practical implication: consistent sleep scheduling 7 days per week is superior to weekday restriction + weekend recovery, and social jet lag minimization is itself a longevity-relevant goal.

How do you know if you have sleep apnea?

Common presentations: loud snoring (though not all OSA patients snore and not all snorers have OSA), witnessed apnea episodes by a bed partner, excessive daytime sleepiness (Epworth Sleepiness Scale ≥10), morning headaches, unrefractive fatigue despite adequate sleep time, frequent nighttime urination, and morning dry mouth. The STOP-BANG questionnaire (8 questions, score ≥3 indicates high risk) is the most validated clinical screening tool. Formal diagnosis requires home sleep apnea testing (HSAT — available without in-lab polysomnography for most uncomplicated adults) or in-laboratory polysomnography. Patients with T2DM, hypertension, atrial fibrillation, or treatment-resistant depression should have particularly low thresholds for OSA screening given the high prevalence and bidirectional consequences in these conditions.

Do sleeping pills affect longevity?

The evidence on prescription sleep medications and longevity is concerning for traditional benzodiazepines and Z-drugs (zolpidem, eszopiclone). These sedative-hypnotics increase GABA-A receptor activity broadly, producing sedation but not physiological sleep — they suppress N3 slow-wave sleep and REM, meaning they may increase subjective sleep time while actually worsening sleep quality on the most biologically important dimensions. A 2012 BMJ Open study found zolpidem users had substantially higher mortality over follow-up, though confounding is difficult to rule out entirely. The newer dual orexin receptor antagonists (DORAs — suvorexant/Belsomra, lemborexant/Dayvigo) work via a different mechanism that better preserves sleep architecture, with emerging evidence of a more favorable safety profile. CBT-I remains the evidence-based first-line approach. Any pharmacological sleep aid should be discussed with a physician in the context of the individual’s complete health picture.

What is the relationship between neuropathy pain at night and sleep quality?

Neuropathic pain has pronounced nocturnal predominance for several reasons: reduction in distracting sensory inputs during quiet wakefulness, thermoregulatory changes during sleep that alter the firing threshold of sensitized C-fibers and Aδ-fibers, reduction in the descending pain inhibitory system (DNIC — diffuse noxious inhibitory controls) that is modulated by sleep/wake state, and the recumbent position that alters blood flow to ischemic peripheral nerves. Pain that disrupts sleep creates a bidirectional pathology: sleep deprivation lowers pain thresholds through central sensitization (sleep deprivation upregulates substance P and reduces endogenous opioid tone), worsening the neuropathic pain on subsequent nights. For DPN patients, neuropathic pain management is inseparable from sleep quality management — treating one without addressing the other produces suboptimal outcomes for both.

The Bottom Line: Sleep Is Not Optional for Longevity

The evidence is unambiguous: sleep is a fundamental biological necessity whose disruption accelerates aging across every measured dimension — epigenetic clock, inflammaging, cardiovascular risk, immune function, metabolic health, and cognitive resilience. The glymphatic system’s dependence on slow-wave sleep for amyloid clearance creates a mechanistically direct link between chronically inadequate sleep and Alzheimer’s disease that should reframe sleep from a lifestyle preference to a clinical priority.

For the 30–35% of American adults sleeping less than 7 hours regularly, the longevity cost is measurable — greater all-cause mortality, higher cardiovascular risk, impaired immune surveillance, accelerated insulin resistance, and potentially increased Alzheimer’s risk. The good news is that sleep quality is highly modifiable through evidence-based behavioral, environmental, and (where necessary) clinical interventions. Sleep apnea, the most common and most consequential treatable sleep disorder, affects the majority of patients with T2DM and DPN — and is dramatically underdiagnosed.

For Dr. Biernacki’s patients managing DPN and T2DM, the DPN-sleep cycle is a specific therapeutic target. Breaking the cycle requires simultaneous attention to glycemic control (reducing nocturia), neuropathic pain management (reducing arousal from burning/tingling), OSA screening and treatment (addressing the most common sleep disorder in this population), and sleep environment and behavioral optimization. Addressing sleep as part of DPN management is not peripheral — it is mechanistically central to the inflammatory, metabolic, and neural repair pathways that determine whether DPN progresses or stabilizes.

Sources and Further Reading

• Xie L, et al. (2013). Sleep drives metabolite clearance from the adult brain. Science, 342(6156), 373–377. [Glymphatic system discovery]
• Nedergaard M, Goldman SA. (2016). Brain drain. Scientific American, 314(3), 44–49.
• Young T, et al. (2008). Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep, 31(8), 1071–1078.
• Liu Y, et al. (2019). Short and long sleep durations are associated with prevalent cardiovascular disease in adults. European Heart Journal, 40(4), 316–325.
• Lim AS, et al. (2017). Sleep fragmentation and the risk of incident Alzheimer’s disease and cognitive decline in older persons. Sleep, 37(10), 1565–1575.
• Spiegel K, et al. (1999). Impact of sleep debt on metabolic and endocrine function. The Lancet, 354(9188), 1435–1439.
• Irwin M, et al. (2010). Sleep disturbance, sleep duration, and inflammation: A systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biological Psychiatry, 80(1), 40–52.
• Ostrin LA, et al. (2017). Attenuation of short wavelengths alters sleep and the ipRGC pupil response. Ophthalmic and Physiological Optics, 37(4), 440–450.
• Depner CM, et al. (2019). Ad libitum weekend recovery sleep fails to prevent metabolic dysregulation during a repeating pattern of insufficient sleep and weekend recovery sleep. Current Biology, 29(6), 957–967.
• Colrain IM, Nicholas CL, Baker FC. (2014). Alcohol and the sleeping brain. Handbook of Clinical Neurology, 125, 415–431.
• Cappuccio FP, et al. (2010). Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep, 33(5), 585–592.

Related Articles

• Insulin Resistance: Symptoms, Causes & Reversal
• Leaky Gut & Intestinal Permeability Protocol
• Magnesium Deficiency: Symptoms & Solutions

Related Compounds

• Autophagy, Fasting & Diabetic Neuropathy
• Berberine/AMPK & Diabetic Neuropathy
• Curcumin (BCM-95) & Diabetic Neuropathy
• Benfotiamine & Diabetic Neuropathy